| 6.37 -0.01 (-0.16%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.56  |
1-year : | 8.83 |
| Resists | First : | 6.47 |
Second : | 7.56 |
| Pivot price | 6.12 |
|||
| Supports | First : | 5.86 |
Second : | 5.48 |
| MAs | MA(5) : | 6.33 |
MA(20) : | 6.04 |
| MA(100) : | 5.27 |
MA(250) : | 4.11 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 92.3 |
D(3) : | 93.9 |
| RSI | RSI(14): 65.1 |
|||
| 52-week | High : | 6.47 | Low : | 2.57 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PBYI ] has closed below upper band by 17.5%. Bollinger Bands are 17.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.48 - 6.53 | 6.53 - 6.55 |
| Low: | 6.24 - 6.29 | 6.29 - 6.33 |
| Close: | 6.3 - 6.38 | 6.38 - 6.43 |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Tue, 13 Jan 2026
Investing in Puma Biotechnology (NASDAQ:PBYI) a year ago would have delivered you a 103% gain - Yahoo Finance
Thu, 08 Jan 2026
Hunt Douglas, SVP at Puma Biotechnology, sells $52,695 in PBYI - Investing.com
Thu, 08 Jan 2026
Auerbach Alan sells Puma Biotechnology (PBYI) shares worth $204k - Investing.com
Wed, 07 Jan 2026
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Tue, 23 Dec 2025
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI) - BioSpace
Sun, 30 Nov 2025
With 60% ownership of the shares, Puma Biotechnology, Inc. (NASDAQ:PBYI) is heavily dominated by institutional owners - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 15.3 (%) |
| Held by Institutions | 71.4 (%) |
| Shares Short | 3,430 (K) |
| Shares Short P.Month | 3,330 (K) |
| EPS | 0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.28 |
| Profit Margin | 17.4 % |
| Operating Margin | 17.5 % |
| Return on Assets (ttm) | 9.8 % |
| Return on Equity (ttm) | 39.6 % |
| Qtrly Rev. Growth | -32.5 % |
| Gross Profit (p.s.) | 3.23 |
| Sales Per Share | 4.2 |
| EBITDA (p.s.) | 0.88 |
| Qtrly Earnings Growth | -58.5 % |
| Operating Cash Flow | 43 (M) |
| Levered Free Cash Flow | 32 (M) |
| PE Ratio | 8.6 |
| PEG Ratio | 0 |
| Price to Book value | 2.78 |
| Price to Sales | 1.51 |
| Price to Cash Flow | 7.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|